List view / Grid view
In this article, Dr Daniel Teper and Dr Chris Arendt explore cellular therapies for cancer that provide an alternative to chimeric antigen receptor (CAR) T-cell therapy. In these Q&As, they outline their important work in immuno-oncology.
Advance your neurodegeneration research with our broad antibody portfolio, ready-to-use ELISA, and cellular kits to develop new efficacious therapies.
Here, Dr Michael Leek describes the benefits of gamma-delta T cells for cancer therapy, exploring why they present a potential alternative to other immuno-oncology platforms.
Using lung basal cell organoids, researchers identify a gene that directs the development of lung cancer and offers a better understanding of its disease treatment.
Development of novel rabbit monoclonal antibodies to characterise microglial activation states in murine models of Alzheimer’s disease.
Researchers have genetically profiled nearly 200,000 cells from lungs, mapping their precise locations in tissue to discover an unexpected new immune niche in our airways.
Need some direction in choosing immune cell markers? Whether you are working with human cells or a mouse model, CST has you covered!
This exclusive interview highlights some of Dr Arthur Suckow’s insights into how his team uses RNA therapies to treat rare diseases such as Charcot-Marie-Tooth 1A.
Researchers have presented comprehensive multi-omic profiles to identify genes, non-coding RNAs, proteins, and plasma metabolites involved in NAFLD-to-NASH progression.
Japanese researchers showed for the first time processes that are crucial targets for treating liver cancer are enhanced by saturated fatty acid diets.
In this article, Drug Target Review’s Izzy Wood and Ria Kakkad share some of the most ground-breaking moments from drug discovery this year.
Read about the current state of the industry, challenges associated with potency assays and measuring product potency throughout the manufacturing process.
Measure protein, DNA and RNA in FFPE tissue samples using rigorously IHC validated CST antibodies on the NanoString® nCounter® platform.
US scientists have developed a potential medication for the genetic cause of ALS and dementia, that eliminates the mutated segments of RNA.
Dr. Stokes, Associate Director Proteomics, discusses how proteomic studies can increase effectiveness, speed of target and biomarker identification.
